Clinical trialPhase 1Active not recruiting
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 10 October 2024
- Expected end
- 14 October 2027
- Enrollment
- 213 participants
- Sites
- 9
- Primary outcomes
- Incidence of adverse events (AEs); Incidence of serious adverse events (SAEs); Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria; Incidence of AEs leading to discontinuation; Incidence of AEs leading to death
- Sponsor
- Industry
- Results posted
- No
- Last update
- 17 April 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).